These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 27514840)

  • 1. Finding all BRCA pathogenic mutation carriers: best practice models.
    Hoogerbrugge N; Jongmans MC
    Eur J Hum Genet; 2016 Sep; 24 Suppl 1(Suppl 1):S19-26. PubMed ID: 27514840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study.
    Høberg-Vetti H; Bjorvatn C; Fiane BE; Aas T; Woie K; Espelid H; Rusken T; Eikesdal HP; Listøl W; Haavind MT; Knappskog PM; Haukanes BI; Steen VM; Hoogerbrugge N
    Eur J Hum Genet; 2016 Jun; 24(6):881-8. PubMed ID: 26350514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical practice guidelines for BRCA1 and BRCA2 genetic testing.
    Pujol P; Barberis M; Beer P; Friedman E; Piulats JM; Capoluongo ED; Garcia Foncillas J; Ray-Coquard I; Penault-Llorca F; Foulkes WD; Turnbull C; Hanson H; Narod S; Arun BK; Aapro MS; Mandel JL; Normanno N; Lambrechts D; Vergote I; Anahory M; Baertschi B; Baudry K; Bignon YJ; Bollet M; Corsini C; Cussenot O; De la Motte Rouge T; Duboys de Labarre M; Duchamp F; Duriez C; Fizazi K; Galibert V; Gladieff L; Gligorov J; Hammel P; Imbert-Bouteille M; Jacot W; Kogut-Kubiak T; Lamy PJ; Nambot S; Neuzillet Y; Olschwang S; Rebillard X; Rey JM; Rideau C; Spano JP; Thomas F; Treilleux I; Vandromme M; Vendrell J; Vintraud M; Zarca D; Hughes KS; Alés Martínez JE
    Eur J Cancer; 2021 Mar; 146():30-47. PubMed ID: 33578357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review on the frequency of BRCA promoter methylation in breast and ovarian carcinomas of BRCA germline mutation carriers: Mutually exclusive, or not?
    Vos S; van Diest PJ; Moelans CB
    Crit Rev Oncol Hematol; 2018 Jul; 127():29-41. PubMed ID: 29891109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Germline BRCA testing is moving from cancer risk assessment to a predictive biomarker for targeting cancer therapeutics.
    Moreno L; Linossi C; Esteban I; Gadea N; Carrasco E; Bonache S; Gutiérrez-Enríquez S; Cruz C; Díez O; Balmaña J
    Clin Transl Oncol; 2016 Oct; 18(10):981-7. PubMed ID: 26742938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic testing in ovarian cancer - clinical impact and current practices.
    Knabben L; Imboden S; Mueller MD
    Horm Mol Biol Clin Investig; 2019 Oct; 41(3):. PubMed ID: 31577534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer.
    Antonucci I; Provenzano M; Sorino L; Balsamo M; Aceto GM; Battista P; Euhus D; Cianchetti E; Ballerini P; Natoli C; Palka G; Stuppia L
    J Hum Genet; 2017 Mar; 62(3):379-387. PubMed ID: 27928164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers.
    Grindedal EM; Heramb C; Karsrud I; Ariansen SL; Mæhle L; Undlien DE; Norum J; Schlichting E
    BMC Cancer; 2017 Jun; 17(1):438. PubMed ID: 28637432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies for recruitment of relatives of BRCA mutation carriers to a genetic testing program in the Bahamas.
    Trottier M; Lunn J; Butler R; Curling D; Turnquest T; Royer R; Akbari MR; Donenberg T; Hurley J; Narod SA
    Clin Genet; 2015 Aug; 88(2):182-6. PubMed ID: 25060751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCAsearch: written pre-test information and BRCA1/2 germline mutation testing in unselected patients with newly diagnosed breast cancer.
    Nilsson MP; Törngren T; Henriksson K; Kristoffersson U; Kvist A; Silfverberg B; Borg Å; Loman N
    Breast Cancer Res Treat; 2018 Feb; 168(1):117-126. PubMed ID: 29164420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer.
    Kemp Z; Turnbull A; Yost S; Seal S; Mahamdallie S; Poyastro-Pearson E; Warren-Perry M; Eccleston A; Tan MM; Teo SH; Turner N; Strydom A; George A; Rahman N
    JAMA Netw Open; 2019 May; 2(5):e194428. PubMed ID: 31125106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Family history predictors of BRCA1/BRCA2 mutation status among Tunisian breast/ovarian cancer families.
    Riahi A; Ghourabi ME; Fourati A; Chaabouni-Bouhamed H
    Breast Cancer; 2017 Mar; 24(2):238-244. PubMed ID: 27025497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives.
    Gori S; Barberis M; Bella MA; Buttitta F; Capoluongo E; Carrera P; Colombo N; Cortesi L; Genuardi M; Gion M; Guarneri V; Incorvaia L; La Verde N; Lorusso D; Marchetti A; Marchetti P; Normanno N; Pasini B; Pensabene M; Pignata S; Radice P; Ricevuto E; Sapino A; Tagliaferri P; Tassone P; Trevisiol C; Truini M; Varesco L; Russo A;
    Crit Rev Oncol Hematol; 2019 Aug; 140():67-72. PubMed ID: 31176273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decisions and ethical issues among BRCA carriers and the use of preimplantation genetic diagnosis.
    Quinn GP; Vadaparampil ST; Bower B; Friedman S; Keefe DL
    Minerva Med; 2009 Oct; 100(5):371-83. PubMed ID: 19910890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selecting Patients with Ovarian Cancer for Germline BRCA Mutation Testing: Findings from Guidelines and a Systematic Literature Review.
    Eccles DM; Balmaña J; Clune J; Ehlken B; Gohlke A; Hirst C; Potter D; Schroeder C; Tyczynski JE; Gomez Garcia EB
    Adv Ther; 2016 Feb; 33(2):129-50. PubMed ID: 26809252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance.
    Eccles DM; Mitchell G; Monteiro AN; Schmutzler R; Couch FJ; Spurdle AB; Gómez-García EB;
    Ann Oncol; 2015 Oct; 26(10):2057-65. PubMed ID: 26153499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1/2 germline testing in non-mucinous epithelial ovarian carcinoma: changing international practice and implications for service provision.
    Coakley M; Cleary V; Power N; O'Reilly S
    Eur J Hum Genet; 2017 Feb; 25(2):167-168. PubMed ID: 27759028
    [No Abstract]   [Full Text] [Related]  

  • 19. BRCA testing in unaffected young women in the United States, 2006-2017.
    Guo F; Scholl M; Fuchs EL; Berenson AB; Kuo YF
    Cancer; 2020 Jan; 126(2):337-343. PubMed ID: 31568561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCA to the future: towards best testing practice in the era of personalised healthcare.
    Capoluongo E
    Eur J Hum Genet; 2016 Sep; 24 Suppl 1(Suppl 1):S1-2. PubMed ID: 27514838
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.